Twitter Logo Youtube Circle Icon LinkedIn Icon

United States > Dispute resolution > Product liability, mass tort and class action: pharmaceuticals and medical devices - plaintiff > Law firm and leading lawyer rankings

Editorial

Index of tables

  1. Product liability, mass tort and class action: pharmaceuticals and medical devices - plaintiff
  2. Leading lawyers

Leading lawyers

  1. 1

Who Represents Who

Find out which law firms are representing which Product liability, mass tort and class action: pharmaceuticals and medical devices - plaintiff clients in United States using The Legal 500's new comprehensive database of law firm/client relationships. Instantly search over 925,000 relationships, including over 83,000 Fortune 500, 46,000 FTSE350 and 13,000 DAX 30 relationships globally. Access is free for in-house lawyers, and by subscription for law firms. For more information, contact david.burgess@legal500.com.

CLICK HERE TO VISIT THE WHO REPRESENTS WHO SITE

Burg Simpson Eldredge Hersh & Jardine, P.C.’s Denver-based group has notable experience handling MDLs and mass tort work. Practice head Michael Burg and Seth Katz represented plaintiffs across the US in a bellwether trial arising from claims of injuries sustained through use of the drug Xarelto. Katz has been leading the representation of a number of plaintiffs in mass tort litigation regarding claims of ovarian cancer developed through use of Johnson & Johnson’s talc-based baby powder product. Meghan Quinlivan acted as a member of the plaintiffs’ steering committee in the power morcellators device MDL arising from claims that the devices increased risk of undiagnosed uterine cancer; the MDL was dissolved in 2016 following the settlement of a majority of the cases.

Trusted Advisor - with Finnegan

IP specialist Finnegan detail how their collaborative approach makes for a unique culture which is designed to allow them to work with clients in a way which is cognizant of the challenges facing all companies today.

Within the drug and device arena, Herman, Herman & Katz LLC’s expertise covers high-profile MDLs and class actions, including appellate work. Leonard Davis, Steve Herman, James Klick and of counsel Joseph Kott have been acting for plaintiffs in the Zofran MDL against GSK arising from allegations of defects. Davis, Klick, Kott and Brian Katz continue to represent clients in claims against a number of defendants concerning the drug Fosamax, which is currently on appeal in a number of jurisdictions. Davis, Russ Herman and Maury Herman continue to act for claimants in testosterone replacement therapy litigation brought against AbbVie and a number of other defendants before the Northern District of Illinois. The firm is headquartered in New Orleans.

Based in Pensacola, Florida, Levin Papantonio Thomas Mitchell Rafferty & Proctor, P.A. has impressive capabilities handling personal injury cases, often obtaining jury verdicts across the US. Troy Rafferty was appointed as one of five members of the plaintiffs’ executive committee in the Abilify MDL brought against Bristol-Myers Squibb and Otsuka Pharmaceuticals before the Northern District of Florida. The firm has also been representing plaintiffs across the US in lawsuits against Janssen Pharmaceuticals arising from allegations of kidney injuries caused by use of the drug Invokana. Mike Papantonio is also recommended.

Based in San Francisco, Lieff Cabraser Heimann & Bernstein, LLP has a diverse prescription drug and device practice. Lexi Hazam has been representing various claimants as a member of the plaintiffs’ executive committee in the Abilify MDL. In New York, Wendy Fleishman was appointed to the plaintiffs’ executive committee in the IVC filter blood clot litigation. The firm continues to represent plaintiffs in a number of medical device claims, including Pinnacle hip injury litigation against Johnson & Johnson and its subsidiary DePuy. Key partners include Elizabeth Cabraser and Robert Nelson.

Headed by W Mark Lanier in Houston, The Lanier Law Firm has strong trial capabilities and experience obtaining significant settlements for plaintiffs. In 2016, the firm obtained a federal jury verdict of more than $1bn for six plaintiffs in the Johnson & Johnson Pinnacle hip implant litigation. Richard Meadow was appointed as one of four members to the plaintiffs’ executive committee in the federal MDL brought against Johnson & Johnson concerning ovarian cancer claims arising from use of the company’s talc-based powder products. Lee Cirsch is now at Capstone Law APC.

Headed by co-founder Christopher Seeger, Seeger Weiss LLP’s personal injury practice has deep experience handling drug injury and medical device litigation, including class actions. In 2017, Seeger was appointed as co-lead counsel of the plaintiffs’ steering committee in the Invokana MDL arising from 55 actions alleging that Janssen Pharmaceuticals’ drug causes injuries, such as diabetic ketoacidosis and kidney damage. David Buchanan continues to serve as liaison counsel in coordinated proceedings concerning Accutane, DePuy hip implants and Yaz/Yasmin. Jeffrey Grand has been acting as a member of the plaintiffs’ steering committee regarding seven federal transvaginal mesh product MDLs. All partners are based in New York.

In Washington DC, Ashcraft & Gerel LLP’s pharmaceutical and medical device group continues to handle a broad range of high-profile litigation. In 2016, Michelle Parfitt was appointed to serve as co-lead counsel in the Johnson & Johnson talc-based powder products MDL before the New Jersey District Court following various judgments against the company in other jurisdictions. Parfitt, Christopher Tisi and veteran litigator James Green have been acting for plaintiffs in morcellator lawsuits arising from claims that the surgical devices increase the risk of spreading unsuspected cancerous tissue in hysterectomies and myomectomies. The team is also currently handling negligent misrepresentation and failure to warn claims brought against Bayer regarding the company’s Essure birth control implant.

Beasley, Allen, Crow, Methvin, Portis & Miles, P.C. has notable experience serving in leadership positions in major drug and device MDLs. In 2017, Danielle Mason was appointed to the plaintiffs’ steering committee for the Invokana MDL consolidated in New Jersey federal court regarding allegations that Janssen Pharmaceuticals’ diabetes drug failed to warn for risks associated with its use. Meanwhile, Leigh O’Dell has been serving as co-lead counsel in the Johnson & Johnson talc MDL regarding allegations that the powder product causes ovarian cancer. The team includes the well-regarded Andy Birchfield, Navan Ward and Frank Woodson.

Under the leadership of Arnold Levin, Howard Sedran and Laurence Berman, Levin Sedran & Berman continues to handle a number of dangerous drug lawsuits, as well as medical malpractice and personal injury matters. Michael Weinkowitz continues to act as a committee member in the Xarelto and Yaz/Yasmin litigation. In the medical device arena, the group has been representing plaintiffs across the US in the Mirena IUD lawsuits and in litigation arising from the 2016 recall of the Stryker femoral head hip implant. The firm is headquartered in Philadelphia.

International comparative guides

Giving the in-house community greater insight to the law and regulations in different jurisdictions.

Select Practice Area

The Legal 500 United States - Events

GC Powerlist -
United States

Press releases

The latest news direct from law firms. If you would like to submit press releases for your firm, send an email request to

Legal Developments worldwide

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to
  • EU and Malta Securitisation Market

    Following the US subprime crisis that began in 2007, the notion of securitisation has suffered from bad press that tainted its reputation. However, securitisation is still considered as an essential component to continued economic recovery and for well-functioning financial markets.
  • PATENTABILITY OF SOFTWARE IN SINGAPORE

     leading_lines_newsletter_dec_2017
  • DOJ Makes the Pilot Program Permanent and Announces FCPA Corporate Enforcement Policy

    The US Department of Justice ("DOJ") had announced a pilot program [1] ("Pilot Program") on April 5, 2016, which created new mitigation opportunities for companies that (i) voluntarily self-disclosed, (ii) cooperated fully, and (iii) took timely and appropriate remedial actions in FCPA matters that fell within the Fraud Section's mandate. The Pilot Program was to remain in effect for 1 year, starting from the day of its announcement. On March 10, 2017, the Acting Assistant Attorney General, Kenneth A. Blanco, announced in a speech that the Pilot Program would continue in full force until the DOJ reached a final decision on whether to extend it, and what revisions, if any, should be made to it. [2] The evaluation period of the Pilot Program ended on November 29, 2017, when Deputy Attorney General Rod Rosenstein announced the new FCPA Enforcement Policy ("Policy"), which effectively makes the Pilot Program permanent with some revisions. According to Deputy Attorney General Rosenstein, the FCPA Unit received 30 voluntary disclosures during the time period that the Pilot Program was in force, as opposed to 18 voluntary disclosures that were received during the previous 18-month period. The Policy has been incorporated into the United States Attorneys' Manual in order to "be readily understood and easily applied by busy prosecutors" as opposed to being promulgated in memorandum format. [3]
  • Effects of State of Emergency Law in Turkey On Prison Sentences Under Criminal Execution Laws

    With the Statutory Decree No.671 dated August 17, 2016, and the recent changes with Regulations No.29987 and No.29824 on Regulation Regarding an Amendment on Placement to Open Punishment Execution Facilities effecting execution of the Law No.5275 on Punishment Execution Law has introduced significant changes.
  • [SOUTH KOREA] Supreme Court Affirms Lower Decision, Finding Invalid the Regulations on Foreign ...

    Supreme Court Affirms Lower Court Decision, Finding Invalid the Regulations on Foreign Exchange Report on Incorporation of Offshore Subsidiary by an Offshore Company
  • Disputes on Health-Related Commercial Advertisements under Consumer Law

    Introduction
  • [SOUTH KOREA] New Administration’s Key Environmental Policies

    To step forward as an environment-friendly government, the Moon Jae-in Administration has announced its key environmental policies, including improving safety in chemical substances and household chemical products, and reinforcing implementation measures of the Paris Agreement.  Under the “sustainable development” paradigm, the new administration will continually promote new regulations to protect the environment and strengthen its enforcement of environmental regulations.
  • [SOUTH KOREA] Lower Court Issues Favorable Decision for 27,000 KIA Motors Employees in an ...

    Lower Court Issues Favorable Decision for 27,000 KIA Motors Employees in an Ordinary Wage Case 
  • SyCipLaw TMT Bulletin: “More Philippine Data Privacy Act: Are you Ready for Phase II?”

    Controllers and processors who have completed Phase I registration with the National Privacy Commission (NPC) will now have to gear up for Phase II. Phase II involves providing the NPC certain information on the organization’s compliance with the Data Privacy Act (DPA).
  • Crowdfunding - The Path towards a regulatory Framework

      The importance and feasibility of crowdfunding platforms is increasing in stature and importance for current and future the entrepreneurs. Malta has recently acceded to the rising trend by creating its first crowdfunding platform, ZAAR, a reward-based crowdfunding platform who has recently been awarded with the first prize in its section at the National Enterprise Support Awards 2016 also as well as being one of the local projects that have represented Malta at the European Enterprise Promotion Awards 2016, held in Slovakia. Nonetheless start-ups based in Malta with global aspirations often rely on international platforms. An increase in interest has emerged amongst the art and culture community as well in social entrepreneurship projects. Crowdfunding in Malta is still at the early stages of development. Despite this, there are endless opportunities for local entrepreneurs and the local business community. Research has shown that through international crowdfunding platforms, monies have been raised for projects in the field of gaming consoles, apps and software as well as for artistic projects.  Testimony to this is a new game design studio in Malta, that launched its first game, Politicks, raised financing through the crowdfunding platform Indiegogo.

Press Releases worldwide

The latest news direct from law firms. If you would like to submit press releases for your firm, send an email request to